Total Neoadjuvant Treatment Combined With Adaptive Radiotherapy for Rectal Cancer — TNT-RECORD  

Rectal Cancer Clinical Trial

Official title: TNT-RECORD:Total Neoadjuvant Treatment in Rectal Cancer With On-couch Adaptive Radiotherapy

Status Recruiting

Clinical Trial Summary

Diarrhea was the most frequently reported severe adverse event in the treatment regime of pre-operative sequential short-course radiotherapy followed by chemotherapy (so called total neo-adjuvant treatment).

This study therefore investigates the benefit of on-couch adaptation for locally advanced rectal cancer patients undergoing this treatment regime.

Clinical Trial Description

This is a prospective single-arm study investigating the benefit of on-couch adaptation for locally advanced rectal cancer patients prescribed with pre-operative sequential short-course radiotherapy (RT) followed by Oxaliplatin-combined chemotherapy (mFOLFOX(6) or CAPOX). On-couch adaptation, where the radiation dose is tailored to the anatomy of the patient at each radiotherapy session. Firstly, the study will investigate if on-couch adaptation result in less gastro-intestinal adverse events, secondly it will reveal if this possible reduction lead to more patients being able to fulfill all cycles of prescribed chemotherapy. ;

Related Conditions & MeSH terms

• Rectal Cancer
• Rectal Neoplasms

• NCT number: NCT05883800
• Study type: Interventional
• Source: Haukeland University Hospital
• Contact: Sara Pilskog, PhD
• Phone: 95890659
• Email: sara.margareta.cecilia.pilskog@helse-bergen.no
• Status: Recruiting
• Phase: N/A
• Start date: June 22, 2023
• Completion date: December 31, 2031